CLINICAL TRIALS PROFILE FOR ILUVIEN
✉ Email this page to a colleague
All Clinical Trials for ILUVIEN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00770770 ↗ | Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina | Terminated | Alimera Sciences | Phase 2 | 2009-05-01 | This study will assess the safety and efficacy of FA Intravitreal Inserts in subjects with macular edema secondary to RVO. |
| NCT01304706 ↗ | Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study | Completed | Alimera Sciences | Phase 3 | 2011-04-01 | This study will assess the safety and utility of the new inserter for the administration of ILUVIEN in subjects with diabetic macular edema. |
| NCT02359526 ↗ | A Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema Patients | Completed | Association for Innovation and Biomedical Research on Light and Image | Phase 4 | 2014-10-01 | To provide treating physicians with experience with ILUVIEN as well as monitoring its safety (and effectiveness) in a real-life chronic diabetic macular edema (DME) patients judged insufficiently responsive to available therapies. |
| NCT02424019 ↗ | Phase 4 IOP Signals Associated With ILUVIEN® | Unknown status | Alimera Sciences | Phase 4 | 2015-05-06 | This study will assess the safety in patients treated with ILUVIEN, with primary focus on IOP. |
| NCT02472366 ↗ | A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Co | Completed | Alimera Sciences | Phase 4 | 2014-01-01 | A phase 4 trial evaluating the effect and safety of ILUVIEN in chronic DME patients insufficiently responsive to available therapies. |
| NCT02902744 ↗ | Fluocinolone Acetonide Insert (ILUVIEN®) for Diabetic Macular Edema (FAD) Study | Withdrawn | Johns Hopkins University | Phase 4 | 2017-03-01 | Primary Objective: • To collect post-approval safety data related to intraocular pressure (IOP) after one or more injections of Iluvien as standard of care in subjects with diabetic macular edema (DME). Secondary Objectives: • To collect visual and anatomic outcome data after one or more injections of Iluvien as standard of care in subjects with diabetic macular edema (DME). |
| NCT03784443 ↗ | Combined Ranibizumab and Iluvien for Diabetic Macular Oedema | Withdrawn | Imperial College London | Phase 2/Phase 3 | 2019-09-01 | This trial investigated whether adding Iluvien sustained release steroid intravitreal eye implant at the beginning of regular anti-VEGF (anti Vascular Endothelial Growth Factor) intravitreal eye injection treatment for diabetic macular oedema would improve disease stability and reduce the need for regular anti-VEGF intravitreal eye injections over first two years. Diabetic macular oedema, accumulation of microscopic fluid at the back of the eye, is a major cause of poor vision in patients with diabetes. This is a double mask randomized control multisite trial, to be conducted at 10 NHS hospital eye clinics in England. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ILUVIEN
Condition Name
Clinical Trial Locations for ILUVIEN
Trials by Country
Clinical Trial Progress for ILUVIEN
Clinical Trial Phase
Clinical Trial Sponsors for ILUVIEN
Sponsor Name
